Century Kangtai Completes Hundreds-of-Millions-Yuan Series A+ and B Funding Rounds, Driving Comprehensive Innovation in Ophthalmic Devices

Recently, Tianjin Century Healthcare Biomedical Engineering Co., Ltd. ("Century Healthcare") announced the completion of its Series A+ and B rounds of financing worth hundreds of millions of yuan.The B-round financing was led by SDIC Chuanghe, with participation from Efung Capital, Dongguan Songshan Lake Science City Venture Capital, VCBeat, and Hangzhou Jinju Investment Management Co., Ltd.The funds raised this time will be used to further accelerate the company's market promotion, consolidate its R&D capabilities, and develop new product lines.

Century Healthcare, founded in 2008 and headquartered in Tianjin, is a national high-tech enterprise. Century Healthcare has obtained Class III medical device registration certificates for multiple ophthalmic products. It also possesses the capability to research, develop, and prepare biomaterials such as collagen. The "collagen sponge" has received a Class III medical device registration certificate from the state, and several other biomaterial projects are currently under development.

As one of the earliest manufacturers in China to produce intraocular lenses, Century Healthcare possesses the capability to research and develop foldable intraocular lenses made from both hydrophilic and hydrophobic materials. Century Healthcare's "Preloaded Hydrophobic Aspheric Intraocular Lens" was approved in July 2023. This product features excellent material properties, combining the dual advantages of hydrophilicity and hydrophobicity, with high implantation efficiency. Its -0.1μm aspheric design optimized by Monte Carlo simulation is a domestic first, offering a larger depth of focus range, effectively resisting postoperative tilt and decentration, and enhancing rotational and axial stability. Clinical feedback has been positive. Additionally, "A Diffractive Multifocal Intraocular Lens Using Intelligent Light Field Distribution Technology" has completed clinical enrollment. The product currently shows excellent clinical trial data, with patients experiencing good vision at all distances, meeting the needs of elderly individuals who wish to remove glasses, and is expected to officially launch in 2024. In the field of optometry, Century Healthcare’s defocus lenses, RGP (Rigid Gas Permeable) lenses, and rigid contact lens care solutions have already been marketed. The "Meishi Ji" multi-focal defocus lens utilizes Fermat spiral bionic technology, achieving innovative progressive defocus distribution, enabling scientific customization of exclusive defocus solutions to meet children’s personalized needs. Century Healthcare also has orthokeratology lenses and scleral lenses in its optometry layout. From myopia prevention and control in adolescents to myopia, presbyopia, and cataract treatment in middle-aged and elderly individuals, Century Healthcare has made comprehensive arrangements, providing eye health solutions for patients of different age groups.

As new products have been successively approved, Century Healthcare's commercialization process has continued to accelerate. The deepening of domestic substitution, the implementation of volume-based procurement, and the combination of excellent products with a talented team have enabled Century Healthcare to quickly establish a good reputation, with rapid revenue growth, emerging as a dark horse in China’s high-end medical device market.

Founder of Century Healthcare, Pei XiujuanExpressed: "We are very grateful for the attention and strong support from both new and existing investment institutions towards Century Healthcare. The company has a robust pipeline of products under development, with multiple products expected to launch each year. Capital support will effectively advance product research and development as well as market expansion, build the company's brand image, facilitate domestically produced alternatives, and move towards the international market. Century Healthcare’s vision is to establish a first-class R&D and production base in the ophthalmology field, striving to become a world-class manufacturer and service technology provider in the ophthalmology sector."

SDIC Chuanghe Biomedical TeamIndicates:“Eye diseases are diverse, with a large patient population. Despite fierce competition, it is a highly distinctive independent track in the medical industry. Century Healthcare has established dual platforms in ophthalmic implantable devices and collagen materials, promoting coordinated development, and possesses a comprehensive innovative platform for ophthalmic optics, materials, and product transformation. The core team has deep industry experience, focusing on R&D, comprehensive planning, strong clinical execution capabilities, and commercialization experience. SDIC Chuanghe (Hangzhou) Venture Capital Management Co., Ltd. will support Century Healthcare in increasing R&D investment, further strengthening its technology and service capabilities, helping it become an innovative and leading enterprise in China's ophthalmic medical device field, benefiting more ophthalmic patients.”

Efung Capital Zhu PaiIndicates:“Ophthalmology, recognized as a golden track, boasts a vast market in both therapeutic areas like cataract treatment and consumer healthcare sectors such as myopia prevention and control, making it one of the key areas that Efung Capital has been focusing on. Century Healthcare is one of the few platform enterprises in ophthalmic consumables that integrates serious medical treatment with consumer healthcare. After obtaining certifications for its full range of monofocal hydrophilic and hydrophobic intraocular lenses (IOLs), the company has continuously expanded and enriched its IOL product line, with more products soon to be launched. Its trifocal IOLs currently in clinical use are expected to surpass international giants and fill domestic gaps. The team demonstrates exceptional R&D capabilities, commercialization ability, and execution. Additionally, Century Healthcare's optometry pipeline has formed a comprehensive product matrix, with multiple products either certified or under rapid clinical development. At the same time, the company continues to build its biomaterials platform, driving expansion through dual engines. We remain highly optimistic about the team’s profound expertise in ophthalmology and biomaterials and will continue to support Century Healthcare’s growth, helping it become a leader in ophthalmic consumables and biomaterials.”